Graves' orbitopathy (GO) is uncommon, but responsible for considerable morbidity. A coordinated approach between healthcare professionals is required in order to meet the needs of patients. Early diagnosis can be achieved by a simple clinical assessment. Low-cost effective interventions can be initiated by generalists, which may improve outcomes. Moderateto-severe GO should be referred to specialised centres. Recommendations for clinical diagnosis, initial management and referral pathways are highlighted.
Introduction
Graves' orbitopathy (GO) is an uncommon, disfi guring and disabling autoimmune condition and more than 90% of cases occur in patients presenting with hyperthyroidism due to Graves' disease. If untreated, GO is characterised by an initial phase of gradual deterioration lasting 6-12 months,
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and then slow improvement lasting for 2-3 years. Optimal treatment improves quality of life. 1 GO is often misdiagnosed as conjunctivitis or allergy. 2 Delays in diagnosis and treatment compromise outcomes. Treatments that can improve visual function and quality of life are often not accessible to patients. 3 
Scope and purpose
The Amsterdam Declaration on Graves' orbitopathy 4 is an international initiative, which highlighted areas requiring improvement in the care of patients with GO, and set targets for earlier diagnosis, referral and treatment. The authors of this guidance are members of the Thyroid Eye Disease Amsterdam Declaration Implementation Group UK (TEAMeD) 5 , which was formed in 2010 to promote the objectives of the Amsterdam Declaration in the UK.
This guidance aims to promote early recognition and improve management of adult patients with GO and identify those who may benefi t from referral to specialised centres.
Recommendations
Levels of evidence were graded according to SIGN 50. 6 These are indicated in each case where the evidence base is stronger than guideline development group experience and opinion alone. Particular good practice points are emphasised thus . Relevant supplementary source data (S1-5) are referred to and available online at http://www.btf-thyroid.org/index. php/campaigns/teamed (S1, common associated symptoms and signs of GO; S2, algorithmic diagnostic criteria for GO; S3, activity and severity assessments for patients with GO; S4, DiaGO (diagnosis of GO): GO clinical assessment tool; S5, early symptoms of GO: information for patients.)
The National Institute of Health and Care Excellence (NICE) has accredited the process used by the Royal College of Physicians to produce the concise clinical guidelines published in Clinical Medicine with effect February 2010 to March 2018 (abstracted guidance) and July 2013 to July 2018 (de novo guidance). More information on accreditation can be viewed at: www.nice.org.uk/about/what-we-do/accreditation.
Guidance for clinicians in primary care and hospital general medicine
GO commonly presents with symptoms of ocular irritation, light sensitivity or watering in the context of new swelling or redness of the eyelids or eyes (Box 1, S1). Note that proptosis may not be present. The majority of patients newly presenting with GO have disturbance of thyroid function, usually hyperthyroidism. The association between smoking and GO is strong and consistent. 7 Selenium supplements in the form of sodium selenite at a dose of 100 µg twice daily (equivalent to 91.3 µg of elemental selenium twice daily), given for 6 months, are benefi cial in patients with active mild GO. 8 Thyroid dysfunction is detrimental to GO. 9 Artifi cial tears can alleviate symptoms of corneal exposure (usually causing grittiness, photophobia and excessive watering) and prevent corneal ulceration. 9 Diplopia is one of the most distressing symptoms of GO. Prisms may provide immediate symptomatic relief and can be adjusted as necessary during the changeable phases of GO. Fig 1) . xii. Refer patients whose dominant clinical features are due to GO directly to tier 3 ( Table 1 , Fig 1) , and if hyperthyroid also to tier 2, unless tier 3 is a joint thyroid eye clinic. xiii. Refer patients with an unclear ophthalmological diagnosis to tier 3 ( Table 1 , Fig 1) .
Guidance for endocrinologists and nuclear medicine physicians
Many patients with GO develop eye disease after the diagnosis of Graves' disease and during follow up in thyroid clinics. All patients with Graves' disease at the time of diagnosis of hyperthyroidism are at risk of developing GO particularly if smokers. Algorithmic diagnostic criteria for GO (S2) and classifi cations of disease activity and severity (S3) are recognised (although the latter require detailed ophthalmological assessments normally beyond the scope of most endocrinologists and nuclear medicine physicians). A simple clinical assessment tool can identify patients in thyroid clinics who may benefi t from referral to a tertiary centre (S4). 12 Awareness of the early symptoms of GO (Box 1) by patients with Graves' disease using an early warning card (S5), may facilitate early diagnosis. Radioiodine may cause exacerbation of GO. 9 If radioiodine is necessary, a course of prophylactic steroids may be indicated unless the GO is inactive, when radioiodine can be administered without steroid prophylaxis. 9 Recommendations i. Make an accurate diagnosis of Graves' disease in all patients presenting with thyrotoxicosis, as this will identify those at risk of GO. ii. Counsel all patients diagnosed with Graves' disease who are smokers about smoking cessation and offer disease-specifi c information 10 and smoking cessation interventions. iii. Give written information about the early symptoms of GO (S5) to all patients diagnosed with Graves' disease. iv. Screen patients with Graves' disease attending thyroid clinics for GO using a brief focused clinical assessment tool (S4). v. Initiate interventions described under 'Guidance for clinicians in primary care and hospital general medicine' above (recommendations iv, v, vi, ix and x) if appropriate. vi. Achieve and maintain euthyroidism as soon as possible (2+, C). vii. Avoid radioiodine unless the eye disease is inactive, as confi rmed by an ophthalmologist experienced in GO.
Otherwise, cover with a course of oral steroids, using prednisone 0.3-0.5 mg/kg 1-3 days after radioiodine and slowly reducing over 3 months (1+, A). viii. Take particular care to avoid hypothyroidism when radioiodine is used. Measure thyroid function every 1-2 months for the fi rst 6 months beginning no later than 4 weeks post-radioiodine. Introduce thyroxine when free T4 levels are low or showing a downward trend within the normal reference range, even in the absence of a raised TSH, as the rise in TSH may be delayed. ix. Patients with inactive GO can be treated with radioiodine without steroid cover, provided hypothyroidism is avoided (2+, C).
Guidance for general ophthalmologists
General ophthalmologists may need to treat emergency complications if tier 3 services are not immediately accessible, but their main role is to ensure that such cases are referred to tier 3, and to an endocrinologist or nuclear medicine physician when thyroid dysfunction is identifi ed (unless the tier 3 service offers a joint thyroid eye clinic). 
Recognition of sight-threatening GO
Sight-threatening GO is rare and can be due to DON, corneal ulceration or globe subluxation. A structured step-wise assessment will help the non-specialist physician determine whether DON is likely, and will guide as to the need for urgent referral (Fig 2) . 'Red fl ag' signs for corneal breakdown can be identifi ed by performing a simple clinical assessment (Fig 3) . The diagnosis of globe subluxation is obvious and patients usually present as an emergency. A history of globe subluxation can be elicited by asking patients appropriate questions (Fig 4) .
Recommendations
i. If sight-threatening GO is suspected, use the algorithms in Figs 2-4 for clinical evaluation. ii. Refer patients with sight-threatening GO urgently to a tier 3 centre (Fig 1) . iii. Refer ophthalmological emergencies occurring out of hours to the nearest emergency eye care services (Fig 1) .
